Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma

BACKGROUND: The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated with pri...

Descripción completa

Detalles Bibliográficos
Autor principal: Gray, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097826/
https://www.ncbi.nlm.nih.gov/pubmed/33952230
http://dx.doi.org/10.1186/s12890-021-01513-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097826/
https://www.ncbi.nlm.nih.gov/pubmed/33952230
http://dx.doi.org/10.1186/s12890-021-01513-7

Ejemplares similares